XML 70 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, € in Millions
1 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
EUR (€)
Dec. 31, 2019
USD ($)
$ / shares
Jan. 01, 2019
USD ($)
Dec. 31, 2018
EUR (€)
Dec. 31, 2018
USD ($)
$ / shares
Jan. 24, 2018
$ / shares
Jan. 23, 2018
$ / shares
Description Of Business And Significant Accounting Policies [Line Items]                    
Preferred stock par value (in USD per share) | $ / shares                 $ 0.001 $ 0
Common stock par value (in USD per share) | $ / shares         $ 0.001     $ 0.001 $ 0.001 $ 0
Accumulated deficit         $ (2,263,563,000) $ (2,223,550,000)   $ (2,224,746,000)    
Available cash and cash equivalents         33,700,000          
Allowance for doubtful accounts from collaborative arrangements         0     0    
Italian VAT receivables         4,400,000     4,500,000    
VAT potential payment       € 4.3 4,800,000          
Foreign currency translation   $ 957,000 $ (1,513,000)              
Finance lease         $ 0          
Capital lease               0    
Leasehold Improvements                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Property and equipment useful life   10 years                
Minimum | Assets Other Than Leasehold Improvements                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Property and equipment useful life   3 years                
Maximum | Assets Other Than Leasehold Improvements                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Property and equipment useful life   5 years                
CTI Life Sciences Limited                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Foreign currency translation   $ 1,300,000 $ (1,500,000)              
Intercompany foreign currency balance receivable             € 28.7 $ 32,800,000    
Aequus Biopharma, Inc                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Interest in majority-owned subsidiary       59.70% 59.70%          
Aequus Biopharma, Inc | Affiliated Entity                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Interest in majority-owned subsidiary       60.00% 60.00%          
Rights Offering | Subsequent Event                    
Description Of Business And Significant Accounting Policies [Line Items]                    
Proceeds from sale of stock $ 59,300,000